CC-100004
Small molecule
CC-100004 is one of 40 small molecule programs targeting Sarcoidosis. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Sarcoidosis
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaApproved
Calciferol
Alnylam PharmaceuticalsApproved
Esbriet
LLegacy Health System
Approved
Ofev
Boehringer IngelheimApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Glucophage
EMD SeronoApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CC-100004. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- UUniversity of Cincinnati